XML 54 R45.htm IDEA: XBRL DOCUMENT
v3.26.1

License Agreements - Additional Information (Details) - USD ($) | 3 Months Ended | 12 Months Ended
--- | --- | ---
Mar. 31, 2026 | Mar. 31, 2025 | Dec. 31, 2025 | Dec. 31, 2022
Schedule Of License Agreement [Line Items] |  |  |  |
Research and development | $ 14,379,000 | $ 15,377,000 |  |
License Agreement |  |  |  |
Schedule Of License Agreement [Line Items] |  |  |  |
Milestone payment |  |  |  | $ 100,000
Written notice period to terminated agreement | 60 days |  |  |
Written notice period to terminated license agreement in event of breach of contract | 30 days |  |  |
Uncured period of agreement in event of breach of agreement notice | 60 days |  |  |
Written notice period for termination of agreement | 90 days |  |  |
Termination period Description | WARF may terminate the License Agreement with 90 days written notice if first commercial sale does not occur before December 31, 2031. Unless terminated earlier by the parties, the term of the License Agreement will continue until the last licensed patent expires in all countries. |  |  |
Research and development |  |  | $ 100,000 |
License Agreement | Maximum |  |  |  |
Schedule Of License Agreement [Line Items] |  |  |  |
Potential milestone payments | $ 800,000 |  |  |
License Agreement | Investigation New Drug (IND) | Maximum |  |  |  |
Schedule Of License Agreement [Line Items] |  |  |  |
Expected milestone payment on achieving certain regulatory and commercial milestones | 17,500,000 |  |  |
License Agreement | Investigation New Drug (IND) | Minimum |  |  |  |
Schedule Of License Agreement [Line Items] |  |  |  |
Expected royalty payments upon first commercial product sale | 100,000 |  |  |
License Agreement | Research and Development |  |  |  |
Schedule Of License Agreement [Line Items] |  |  |  |
Upfront payment upon execution of agreement | $ 300,000 |  |  |

X
- Definition Expected milestone payment on achieving certain regulatory and commercial milestones. + References No definition available. + Details
Name: | dsgn_ExpectedMilestonePaymentOnAchievingCertainRegulatoryAndCommercialMilestones
Namespace Prefix: | dsgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Expected royalty payments upon first commercial product sale. + References No definition available. + Details
Name: | dsgn_ExpectedRoyaltyPaymentsUponFirstCommercialProductSale
Namespace Prefix: | dsgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Milestone payment + References No definition available. + Details
Name: | dsgn_MilestonePayment
Namespace Prefix: | dsgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Notice period description. + References No definition available. + Details
Name: | dsgn_NoticePeriodDescription
Namespace Prefix: | dsgn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Notice period for termination of agreement. + References No definition available. + Details
Name: | dsgn_NoticePeriodForTerminationOfAgreement
Namespace Prefix: | dsgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Potential milestone payments. + References No definition available. + Details
Name: | dsgn_PotentialMilestonePayments
Namespace Prefix: | dsgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Schedule of license agreement. + References No definition available. + Details
Name: | dsgn_ScheduleOfLicenseAgreementLineItems
Namespace Prefix: | dsgn_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Uncured period of agreement in event of breach of agreement notice. + References No definition available. + Details
Name: | dsgn_UncuredPeriodOfAgreementInEventOfBreachOfAgreementNotice
Namespace Prefix: | dsgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Upfront payment upon execution of agreement. + References No definition available. + Details
Name: | dsgn_UpfrontPaymentUponExecutionOfAgreement
Namespace Prefix: | dsgn_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Written Notice period to terminated agreement. + References No definition available. + Details
Name: | dsgn_WrittenNoticePeriodToTerminatedAgreement
Namespace Prefix: | dsgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Written notice period to terminated license agreement in event of breach of agreement. + References No definition available. + Details
Name: | dsgn_WrittenNoticePeriodToTerminatedLicenseAgreementInEventOfBreachOfAgreement
Namespace Prefix: | dsgn_
Data Type: | xbrli:durationItemType
Balance Type: | na
Period Type: | duration

X
- Definition Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity. + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 18 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18 Reference 2: http://www.xbrl.org/2003/role/exampleRef -Topic 220 -SubTopic 40 -Name Accounting Standards Codification -Section 55 -Paragraph 14 -Publisher FASB -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14 Reference 3: http://www.xbrl.org/2003/role/exampleRef -Topic 280 -SubTopic 10 -Name Accounting Standards Codification -Section 55 -Paragraph 48 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Topic 985 -SubTopic 20 -Name Accounting Standards Codification -Section 50 -Paragraph 2 -Publisher FASB -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Topic 730 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1 Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef -Topic 912 -SubTopic 730 -Name Accounting Standards Codification -Section 25 -Paragraph 1 -Publisher FASB -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1 + Details
Name: | us-gaap_ResearchAndDevelopmentExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=dsgn_LicenseAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=dsgn_InvestigationNewDrugMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |